#USA #New York #Hoth Therapeutics #VA Department #Obesity Treatment

Hoth Therapeutics and the Department of Veterans Affairs Join Forces

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to innovative therapy development, recently revealed its exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA). This alliance aims to address significant health challenges through the development of effective obesity treatments.

A Landmark Partnership

This partnership is built on a jointly developed patent portfolio, co-created by Hoth Therapeutics, the VA, and Emory University. The technology focuses on utilizing Glial Cell Line-Derived Neurotrophic Factor (GDNF) to tackle obesity and its related health issues. This advance in research and collaboration is a testament to Hoth's commitment to pioneering solutions in healthcare.

Robb Knie, the CEO of Hoth Therapeutics, expressed pride in collaborating with esteemed institutions like the VA and Emory University. He emphasized that this agreement represents a crucial step toward addressing obesity, tapping into innovative, science-driven strategies to enhance patient outcomes worldwide.

Developing the Future of Obesity Treatment

Under the terms of the deal, Hoth Therapeutics gains exclusive rights to develop, market, and commercialize products stemming from the licensed patents. This comprehensive arrangement ensures that the technology progresses smoothly from the research phase through to commercialization, ultimately benefiting a broad audience in need of effective treatment options.

Hoth Therapeutics plans to leverage its significant expertise and resources, meticulously adhering to development milestones as it brings this potentially life-changing product to market. The company is aware of the pressing need for better obesity treatments and is committed to using scientific discoveries to create therapeutic solutions.

Expansion of Intellectual Property

In conjunction with the agreement with the VA, Hoth has also signed a Letter of Intent (LOI) to further secure its intellectual property. This includes additional provisional patent protection for its lead therapeutic, HT-001, which now extends to other cancer therapeutics. This strategic move not only bolsters Hoth's market position but also enhances its development capability in potentially transformative treatments.

About Hoth Therapeutics

Hoth Therapeutics is a clinical-stage biopharmaceutical firm focused on creating impactful treatments aimed at improving patient quality of life. The company operates at the forefront of early-stage pharmaceutical research and development, striving to elevate drugs from initial stages to clinical testing. Their patient-centric approach involves collaborations with scientists, clinicians, and key opinion leaders to explore therapeutics that could lead to breakthroughs and broaden treatment varieties.

For more detailed information about Hoth Therapeutics and its mission, visit Hoth Therapeutics Investor Relations.

Looking Ahead

Hoth Therapeutics' partnership with the VA represents a significant milestone in the development of effective obesity treatments, showcasing the potential of collaborative innovation in addressing pressing health issues. As they move forward, Hoth aims to ensure that these novel therapies are developed with a strong focus on efficacy, safety, and accessibility, ultimately aiming to transform the lives of many struggling with obesity and related diseases.